Brennan M J, Donegan W L, Appleby D E
Am J Surg. 1979 Feb;137(2):260-2. doi: 10.1016/0002-9610(79)90159-4.
Estrogen receptor protein (ERP) concentrations were determined by the sucrose diffusion method in primary tumors and one or more metastases in twenty-nine patients with breast cancer. Concurrence of ERP concentrations between primaries and at least some metastases was found in 76 per cent of cases. Multiple metastases were assayed in ten cases, three of which demonstrated highly variable concentrations. It was concluded that clinically significant differences in ERP concentrations often exist between primary breast cancers and their metastases as well as between different metastases from the same tumor, accounting for the lack of responsiveness of some ERP-"positive" tumors and for mixed responses to hormonal or endocrine therapy. Assay of an isolated metastasis may be no more reliable in predicting overall patient benefit from therapy than assay of the primary itself.
采用蔗糖扩散法测定了29例乳腺癌患者原发肿瘤及一个或多个转移灶中雌激素受体蛋白（ERP）的浓度。在76%的病例中发现原发灶与至少部分转移灶的ERP浓度一致。对10例患者的多个转移灶进行了检测，其中3例显示浓度变化很大。得出的结论是，原发性乳腺癌及其转移灶之间以及同一肿瘤的不同转移灶之间，ERP浓度往往存在临床上的显著差异，这解释了一些ERP“阳性”肿瘤缺乏反应性以及对激素或内分泌治疗出现混合反应的原因。检测单个转移灶在预测患者从治疗中获得的总体益处方面可能并不比检测原发灶更可靠。
